• 1
    Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH for the Canadian Psoriasis Guidelines Committee.Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol2012; 16: 241251.
  • 2
    Kimball AB, Gordon KB, Fakharzadeh S et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol2012; 166: 861872.
  • 3
    Leonardi C, Kimball AB, Papp KA et al. , for the PHOENIX 1 study investigators.Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet2008; 371: 16651674.
  • 4
    Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica1978; 157: 238244.
  • 5
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol1994; 19: 210216.
  • 6
    Geng D, Shankar G, Schantz A Rajadhyakshe M, Davis H Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal2005; 39: 364375.
  • 7
    C5 Research. C5 Research, Cleveland Clinic Coordinating Center for Clinical Research. [WWW document] URL (last accessed: 25 July 2012).
  • 8
    Papp K, Crowley J, Ortonne J-P et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol2011; 164: 434441.
  • 9
    Reich K, Nestle FO, Papp K et al. , for the EXPRESS study investigators. (period)Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet2005; 366: 13671374.
  • 10
    Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet2006; 367: 2935.
  • 11
    Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol2012; 166: 179188.
  • 12
    Lucka TC, Pathirana D, Sammain A et al. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systemic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol2012; 26: 1331–1334.
  • 13
    Patel RV, Shelling ML, Prodanovich S, Federman DG, Kirsner RS. Psoriasis and vascular disease—risk factors and outcomes: a systemic review of the literature. J Gen Intern Med2011; 26: 10361049.
  • 14
    Reich K, Langley RG, Lebwohl M et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol2011; 164: 862872.
  • 15
    Ryan C, Leonardi CL, Krueger JG et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA2011; 306: 864871.
  • 16
    Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol2012; doi: 10.1111/j.1468-3083.2012.04500.x. [Epub ahead of print].
  • 17
    Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. on behalf of the PSOLAR investigators and Steering Committee. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol2012; 11: 12101217.